Picture of Sellas Life Sciences logo

SLS Sellas Life Sciences Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapMomentum Trap

Momentum

Relative Strength (%)
1m-0.49%
3m+29.28%
6m+13.84%
1yr-26.64%
Volume Change (%)
10d/3m-23.59%
Price vs... (%)
52w High-21.63%
50d MA+6.64%
200d MA+31.24%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-362.44%
Return on Equity-313.39%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Sellas Life Sciences EPS forecast chart

Profile Summary

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of novel therapeutics for a range of cancer indications. The Company's product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor. GPS is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.

Directors

Last Annual
December 31st, 2023
Last Interim
March 31st, 2024
Incorporated
April 3rd, 2006
Public Since
March 12th, 2008
No. of Shareholders
35
No. of Employees
16
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Capital Market
Shares in Issue
57,754,928

SLS Share Price Performance

Upcoming Events for SLS

Sellas Life Sciences Group Inc Annual Shareholders Meeting

Sellas Life Sciences Group Inc Annual Shareholders Meeting

Q2 2024 Sellas Life Sciences Group Inc Earnings Release

Q3 2024 Sellas Life Sciences Group Inc Earnings Release

Similar to SLS

Picture of 180 Life Sciences logo

180 Life Sciences

us flag iconNASDAQ Capital Market

Picture of Abeona Therapeutics logo

Abeona Therapeutics

us flag iconNASDAQ Capital Market

Picture of ABVC Biopharma logo

ABVC Biopharma

us flag iconNASDAQ Capital Market

Picture of Acesis Holdings logo

Acesis Holdings

us flag iconNASDAQ Capital Market

Picture of Achieve Life Sciences logo

Achieve Life Sciences

us flag iconNASDAQ Capital Market

FAQ